RSS Facebook Twitter YouTube

Related Issues

Vaccine can fight different malaria strains

HT Staff Read Article
Published: 02/28/17

Plasmodium_falciparum_blood_smear_Credit_CDC-Mae_Melvin_220.png
A macro- and microgametocyte
of the P falciparum parasite
Image from CDC/Mae Melvin

An investigational malaria vaccine can protect healthy adults from infection with a malaria strain different from that contained in the vaccine, according to a phase 1 study published in PNAS. The vaccine, known as the PfSPZ Vaccine, contains weakened Plasmodium falciparum sporozoites that are able to generate a protective immune response against live malaria infection. Prior research showed that the PfSPZ Vaccine . . . [Read Article]

CHMP recommends authorization of antiemetic agent

HT Staff Read Article
Published: 02/27/17

patient_receives_chemo_older_woman_Credit_Rhoda_Baer_220.jpg
Cancer patient
receiving chemotherapy
Photo by Rhoda Baer

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the antiemetic agent rolapitant (Varuby) as a treatment for adults with cancer. The drug is intended to be used in combination with other antiemetic agents to prevent delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. [Read Article]

First case of artemisinin resistance in Africa

HT Staff Read Article
Published: 02/24/17

plasmodium_parasite_infecting_an_RBC_credit_StJudeChildrensResearchHospital_195.jpg
Plasmodium parasite
infecting a red blood cell
Image from St. Jude
Children’s Research Hospital

Researchers have identified the first known case of artemisinin-resistant malaria originating in Africa, according to a letter published in NEJM. Resistant Plasmodium falciparum parasites were detected in a Chinese man who had travelled from Equatorial Guinea to China. The finding means Africa has joined Southeast Asia in hosting parasites that are partially resistant to the first-line antimalaria drug, artemisinin. [Read Article]

Software predicts HSPC differentiation

HT Staff Read Article
Published: 02/23/17

cells-megakaryocytic-erythroid-lineage-HelmholtzZentrumMunchen-180.png
Cells with expressed markers
for the megakaryocytic/
erythroid lineage
Image courtesy of
Helmholtz Zentrum München

Deep learning can be used to determine how murine hematopoietic stem and progenitor cells (HSPCs) will differentiate, according to research published in Nature Methods. Deep learning algorithms simulate the learning processes in people using artificial neural networks. Researchers have reported the development of software that uses deep learning to predict which type of cell murine HSPCs will differentiate into, based on microscopy images. [Read Article]

How long Zika remains in body fluids

HT Staff Read Article
Published: 02/20/17

blood_sample_collection_Juan_D_ Alfonso_230.jpg
Blood sample collection
Photo by Juan D. Alfonso

A study published in NEJM provides evidence that Zika virus RNA remain longer in blood and semen than in other body fluids, which suggests these may be superior diagnostic specimens. This is the first study in which researchers examined multiple body fluids for the presence of Zika virus over a length of time. The team sought to determine the frequency and duration of detectable Zika virus RNA in serum, saliva, urine, semen, and vaginal secretions. [Read Article]

 

{title}

{icon} {author} Read Article
Published: {pubDate}

{summary}